NCT00103818
Completed
Phase 3
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Efficacy Study of MK0928 15 mg and 10 mg in the Treatment of Adult Outpatients With Primary Insomnia
ConditionsInsomnia
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Insomnia
- Sponsor
- H. Lundbeck A/S
- Enrollment
- 900
- Primary Endpoint
- Patient-reported amount of sleep and time to fall asleep at night after 3 months
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of MK0928 for insomnia (a sleep disorder).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adult outpatients who are between the ages of 18 and 64
Exclusion Criteria
- •Adults who do not have a diagnosis of insomnia (a sleep disorder)
Outcomes
Primary Outcomes
Patient-reported amount of sleep and time to fall asleep at night after 3 months
Time Frame: After 3 months
Secondary Outcomes
- Sleep quality(After 3 months)
- Patient-reported awakenings at night(After 3 months)
- Functioning after 3 months(After 3 months)
Similar Trials
Completed
Phase 3
Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)InsomniaNCT00095069H. Lundbeck A/S600
Completed
Phase 3
Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)InsomniaNCT00095043H. Lundbeck A/S320
Terminated
Phase 2
Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)Primary InsomniaNCT00266357H. Lundbeck A/S50
Completed
Phase 2
MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)Primary InsomniaNCT00266344H. Lundbeck A/S520
Withdrawn
Phase 3
An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)InsomniaNCT00102154H. Lundbeck A/S